a Candiolo Cancer Institute-FPO- IRCCS , Turin , Italy .
b Department of Oncology , University of Torino , Turin , Italy.
Expert Opin Biol Ther. 2018 Apr;18(4):359-367. doi: 10.1080/14712598.2018.1425679. Epub 2018 Jan 10.
Epithelial ovarian cancer (EOC) is the most common cause of death among gynecological malignancies. Despite surgical and pharmacological efforts to improve patients' outcome, persistent and recurrent EOC remains an un-eradicable disease. Chimeric associated antigens (CAR) T cells are T lymphocytes expressing an engineered T cell receptor that activate the immune response after an MHC unrestricted recognition of specific antigens, including tumor associated antigens (TAAs). CART cells have been shown to be effective in the treatment of hematologic tumors even if frequently associated with potentially severe toxicity and high production costs.
In this review, we will focus on preclinical and clinical studies evaluating CART activity in EOC in order to identify possible difficulties and advantages of their use in this particular setting.
The pattern of diffusion within the peritoneal cavity, the tumor microenvironment and the high rate of TAAs make EOC a particularly interesting model for CART cells use. Data from preclinical studies indicate a potential activity of CARTs in EOC, but robust clinical data are still awaited. Further studies are needed to determine the best methods of administration and the most effective CAR type to treat EOC patients.
上皮性卵巢癌（EOC）是妇科恶性肿瘤中导致死亡的最常见原因。尽管在手术和药物方面做出了努力以改善患者的预后，但持续性和复发性 EOC 仍然是一种无法根治的疾病。嵌合相关抗原（CAR）T 细胞是表达经工程改造的 T 细胞受体的 T 淋巴细胞，在 MHC 不受限制地识别特定抗原（包括肿瘤相关抗原（TAA））后激活免疫反应。CAR T 细胞已被证明在治疗血液系统肿瘤方面非常有效，即使它们经常与潜在的严重毒性和高生产成本相关。
在这篇综述中，我们将重点介绍评估 CAR T 细胞在 EOC 中活性的临床前和临床研究，以确定在这种特定环境中使用它们的可能困难和优势。
在腹腔内扩散的模式、肿瘤微环境和 TAA 的高发生率使得 EOC 成为 CAR T 细胞使用的一个特别有趣的模型。来自临床前研究的数据表明 CAR T 细胞在 EOC 中具有潜在的活性，但仍需要更多的临床数据。需要进一步的研究来确定治疗 EOC 患者的最佳给药方法和最有效的 CAR 类型。
